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Abstract  
In searching for better anticonvulsant drug and the importance of 2,5-disubstituted 1,3,4-oxadiazoles, 2-amino-5- 
{2-[(2,6-dichlorophenyl)amino]benzyl}-1,3,4-oxadiazole (1), 1-(5-{2-[(2,6-dichlorophenyl)amino]benzyl}-1,3,4- 
oxadiazol-2-yl)-urea (2) and N-(5-{2-[(2,6-dichlorophenyl) amino]benzyl}-1,3,4-oxadiazol-2-yl)-hydrazine carbox-amide 
(3) and  N1-(5-{2-[(2,6-dichlorophenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-(4-substituted benzaldehyde) 
-semicarbazones (4a-f) and N1-(5-{2-[(2,6-dichloro phenyl) amino] benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-substituted 
phenyl) ethanone]-semicarbazone (5a-d) and N1-(5-{2-[(2,6-dichlorophenyl) amino]benzyl}-1,3,4-oxadiazol-2-yl) 
-N4-[1-(4-substituted henyl) (phenyl) methanone]-semicarbazones (6a-d) were evaluated for their anticonvulsant activity. 
Among all the compounds, 6b emerged out as the most potent compound. The anticonvulsant activity of 7-alkoxy- 
triazolo-[3,4-b]benzo[d]thiazoles (7a-u). Most compounds showed good anticonvulsant activity. Compound (7g) was 
found to be the most potent compound. A series of 2-(1H-Benzotriazol-1-yl)-N'-[substituted]acetohydrazides (8a-j) were 
tested for anticonvulsant activity and the most active compound was (8i). Various 6-phenyl-7H-[1,2,4]triazolo [3,4-b] 
[1,3,4] thiadiazines (9a-n) fused with 1,2,4-triazoles. Most compounds showed some degree of anticonvulsant activity. 
Compound (9h) was the most promising compound. A series of benzothiazole sulfonamides, 2-Amino-1,3-benzothiazoles 
(10a-c), 6-Sulfamido-1,3-benzothiazo-2-yl-thiosemicarbazides (11a-c) and N-[(1,3-benzothiazole-2-ylamino) 
(imino)methyl]-nitro-benzene sulfonamides 12a-b  were tested for the anticonvulsant activity. The significant results 
were found with compounds (11c) and (10c). Compound (10c), (11c) and compound (10b) were found to be raised in the 
onset of convulsion and other test drugs showed moderate protection. 
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Introduction  
Epilepsy is recognized as a neurological disorder, affecting a large section of people both male and 
female across the world. Every year about 2,50,000 new cases are added to this figure. Epilepsy 
also poses a considerable economic burden on the society. The direct costs of epilepsy vary 
significantly depending on the severity of the disease and the response to the treatment. The known 
potential causes of epilepsy include brain tumors, infections, traumatic head injuries, perinatal 
insults, developmental malformations, cerebrovascular diseases, febrile seizures and status 
epilepticus (Loscher. 2002). Many patients have seizures that are resistant to the available 
antiepileptic drugs (AEDs). Although 70–80% of epileptics are currently controlled by a variety of 
drugs, seizure protection is often accompanied by numerous side effects including drowsiness, 
ataxia, gastrointestinal disturbances, gingival hyperplasia, hirsutism, and megaloblastic anemia. 
The older ‘first generation’ AEDs are phenobarbitol, carbamazepine, valproic acid and newer 
‘second generation’ AEDs are lamotrigine, topiramate, vigabatrin, tiagabine, gabapentin and 
levetiracetam (Brazil and Pedly. 1998; McCabe. 2000). The selection of an AEDs for the treatment 
is predicated on its efficacy for the specific type of seizures,  tolerability and safety (Regesta and 
Tanganelli. 1999; Kwan and Brodie. 2000). Therefore, it is essential to search for newer chemical 
entities for the therapy of epilepsy (Cosford et al., 1998). The 3-piperidinecarboxylic acid 
(nipecotic acid) has become an emerging new class of potent anticonvulsants.  
Epilepsy results from a temporary electrical disturbance of the brain due to an imbalance 
between excitatory and inhibitory neurotransmitters. The mechanisms of action of the AEDs consist 
in the blockade of voltage-dependent Na
+
 channels or T-type Ca
2+
 channels, inhibition of 
glutamatergic transmission and facilitation of γ-aminobutyric acid (GABA) inhibitory 
neurotransmission (Strine, et al., 2005; Mc Namara et al., 2006; Thiry et al., 2008; Kaindl et al., 
2006). However, 30% of epileptic patients continue to have seizures despite optimized treatment 
with classical AEDs. Moreover, many serious side effects are reported in many patients treated with 
presently available AEDs. There is a growing interest for new AEDs acting on novel therapeutic 
targets with a pharmacological profile characterized by enhanced efficacy and minimal side effects. 
This needs to be coupled with a better understanding of generation of seizures (Willams and Lamke. 
2002; Fisher et al., 2005). Epilepsy also affects about 4% of individuals over their lifetime. Despite 
the development of several new AEDs, over 30% of people with epilepsy do not have seizure 
control and others do so only at the expense of significant dose-related toxicity and peculiar 
adverse effects that range in harshness from minimal brain impairment to death from aplastic 
anemia or hepatic failure (Brown and Holmes. 2001). Thus, have there is an immense need for the 
development of more effective and safer AEDs. Several investigations have also revealed the 
anticonvulsant potential of 1,3,4-oxadiazole analogs (Zarghi et al., 2005; Almasirad et al., 2004). A 
pharmacophoric model has been proposed for anticonvulsant activity as a result of conformational 
studies on existing AEDs, such as Phenytoin, Carbamazepine, Rufinamide and Phenobarbitone 
(Pandeya et al., 1999).  
Benzotriazole derivatives constitute an important class of heterocyclic compounds and present a 
wide range of bioactivities. Among the most important are: anticonvulsant (Dawood et al., 2006; 
Rajasekaran et al., 2006; Srivastava and Rawat. 1999), CNS depressant, antimicrobial (Nanjunda et 
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al., 2006; Omran et al., 2009), anticancer (Zhang et al., 2008), analgesic and anti-inflammatory 
activity (Purohit and Srivastava. 1992). Several derivatives of benzotriazole are reported as 
agonists of peroxisome proliferator activated receptors (Sparatore et al., 2006). The 1,2,4-triazoles 
and their fused heterocyclic derivatives have received considerable attention owing to thei r 
synthetic and effective biological importance. For example, a triazolothiadiazine system may be 
viewed as a cyclic analog of thiosemicarbazide, the latter often displays antimicrobial (Plech et al., 
2011), anticancer (Vrdoljak et al., 2010), and anticonvulsant activities (Jain et al., 2010; Gülerman 
et al., 1997; Gürsoy and Karali. 1995). For this reason and in continuation to efforts directed toward 
the synthesis of new heterocyclic compounds with anticonvulsant biological activities. A series of 
condensed system, which combine two biolabile components (1,2,4-triazole and [1,3,4]thiadiazine) 
in a ring together to give a compact and moderate rigid structure, and evaluated them for their 
anticonvulsant profile after subtle structural modification. The carbonic anhydrase (CA) inhibitor 
acetazolamide (AZA) is used as an AED in the treatment of epilepsy having sulfonamide group. 
Despite the development of a rapid tolerance consisting in diminished therapeutic efficacy after the 
initial response of the patients, AZA is still used in combination therapy with other AEDs or in 
refractory epilepsies (Garrison et al., 1991). Zonisamide another sulfonamide with CA inhibitory 
properties is also used as adjunctive therapy for refractory partial seizures in adult (Supuran. 2007; 
Supuran. 2008). Its sulfamoyl group was expected to suppress seizures in a s imilar way to AZA 
through the inhibition of carbonic anhydrase (Supuran and Scozzafava. 2007; Simone et al., 2005; 
Joo et al., 2010; Basaran et al., 2008). However, this does not appear to be the only primary 
mechanism of action. The sulfamate, topiramate is a recent antiepileptic drug which has been 
shown to be clinically effective against different types of seizures (Casini et al., 2003; Chegwidden 
et al., 2000; Herrero et al., 2002; Supuran et al., 2003). Basic ring having the sulfonamide group of 
benzothiazole ring system have various pharmacological activity. Various 
2-amino-1,3-benzothiazoles were tested for neurotoxicity and anticonvulsant study. In this respect, 
we prompted to prepare a new class of heterocyclic sulphonamides and study their anticonvulsant 
activity. In order to obtain some information about the activity of synthesized compounds, 
anticonvulsant activity was tested by Maximal electroshock (MES) seizure model and their 
neurotoxic effects were determined by rotorod test. 
Antiepileptic activities of various heterocyclic compounds  
In searching for better anticonvulsant drug and the importance of semicarbazones and 
2,5-disubstituted 1,3,4-oxadiazoles such as 2-amino-5-{2-[(2,6-dichlorophenyl)amino] benzyl}- 
1,3,4-oxadiazole (1), 1-(5-{2-[(2,6-dichlorophenyl) amino]benzyl}-1,3,4- oxadiazol-2-yl)-urea (2) 
and N-(5-{2-[(2,6-dichlorophenyl) amino]benzyl}-1,3,4-oxadiazol-2-yl) -hydrazine carboxamide 
(3) and  N1-(5-{2-[(2,6-dichlorophenyl)amino]benzyl}-1,3,4- oxadiazol- 2-yl)-N4-(4-substituted 
benzaldehyde)-semicarbazone (4a-f), N1-(5-{2-[(2,6-dichloro phenyl)amino]benzyl}-1,3,4- 
oxadiazol-2-yl)-N4-(benzaldehyde) -semicarbazone (4a), N1-(5-{2-[(2,6-dichloro phenyl)amino] 
benzyl}-1,3,4-oxadiazol-2-yl)-N4-(4-nitro-benzaldehyde)-semicarbazone (4b), N1-(5-{2-[(2,6- 
dichlorophenyl) amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-(4-hydroxy benzaldehyde)-semi- 
carbazone (4c), N1-(5-{2-[(2,6-dichlorophenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4- 
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(4-methyl- benzaldehyde)-semicarbazone (4d), N1-(5-{2-[(2,6- dichlorophenyl) amino]benzyl} 
-1,3,4-oxadiazol-2-yl)-N4-(4-methoxybenzaldehyde)- semi- carbazone (4e), and N1-(5-{2- 
[(2,6-dichloro-phenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-(4-chlorobenzaldehyde)- semi- 
carbazone (4f) and N1-(5-{2-[(2,6-dichloro phenyl)amino] benzyl}-1,3,4-oxadiazol-2-yl)- 
N4-[1-(4-substituted phenyl) ethanone]-semicarbazone (5a-d) namely N1-(5-{2-[(2,6-dichloro 
phenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-hydroxy phenyl)-ethanone]-semicarbazone 
(5a), N1-(5-{2-[(2,6-dichlorophenyl) amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-methoxy 
phenyl)-ethanone]-semicarbazone (5b), N1-(5-{2-[(2,6-dichlorophenyl)amino]benzyl}-1,3,4- 
oxadiazol-2-yl)-N4-[1-(4-nitrophenyl)-ethanone]-semicarbazone (3c) and N1-(5-{2-[(2,6-dichloro- 
phenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-chlorophenyl)-ethanone]-semicarbazone 
(5d) and N1-(5-{2-[(2,6-dichlorophenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-substituted 
phenyl) (phenyl) methanone]-semicarbazone (6a-d) namely N1-(5-{2-[(2,6-dichlorophenyl)amino] 
benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(diphenyl) methanone]-semicarbazone (6a), N1-(5-{2-[(2,6- 
dichloro-phenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-hydroxyphenyl) (phenyl) 
methanone]-semicarbazone (6b), N1-(5-{2-[(2,6-dichloro phenyl)amino]benzyl}-1,3,4-oxadiazol 
-2-yl)-N4-[1-(4-nitrophenyl) (phenyl) methanone]-semicarbazone (6c) and N1-(5-{2-[(2,6 
-dichloro-phenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-methoxyphenyl) (phenyl) metha- 
none]-semicarbazone (6d) were evaluated for their anticonvulsant activity. Among all the 
compounds, N1-(5-{2-[(2,6-dichlorophenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4- 
hydroxyl-phenyl)(phenyl) methanone]-semicarbazone 6b emerged out as the most potent compound, 
showing considerable activity in maximal electroshock seizure (at 100 mg/kg after 0.5 h and at 300 
mg/kg after 4.0 h) and subcutaneous pentylenetrtrazole model (at 300 mg/kg after 4.0 h) without 
any neurotoxicity (up to 300 mg/kg after 4.0 h). The results of the present study vali dated that the 
pharmacophore model with four binding sites is essential for anticonvulsant activity.  
Anticonvulsant Activity 
The anticonvulsant screening was performed using male albino mice (swiss, 18 -25 g) and rat 
(wistar 100-150 g). The anticonvulsant potential of the test compounds was assessed by two models 
namely, maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole (scPTZ) models. 
Acute neurological toxicity in mice was evaluated by rotorod test [16]. All the synthesized 
compounds were screened for their anticonvulsant potential through MES and scPTZ models in 
doses of 30, 100, 300 mg/kg by intraperitoneal (i.p.) injection. The data indicates that 64% of the 
compounds i.e., 4a, 4c, 4f, 5a, 5c, 6a, 6b, 6c, and 6d were active in the MES screening as compared 
to 35% of the compounds i.e., 4e, 5a, 5d, and 6b in the ScPTZ test. Thus, the compounds displayed 
some MES selectivity. The majority of the compounds i.e., 4a, 4c, 4e to 5a, and 5c to 6d showed 
activity in either of the MES or ScPTZ models after 4 h, indicating that the test compounds are 
slow acting anticonvulsants (Tables 1 and 2). On critical overview of synthesized compounds, it has 
been found that compounds bearing the groups like hydroxy, nitro on distant phenyl ring possess 
high potency in MES and scPTZ tests. Whereas, replacement of these groups with methoxy and 
methyl groups on the distant phenyl ring has resulted in compounds with decrease in anticonvulsant 
activity. Replacement of the proton on the carbimino carbon atom by methyl group i.e., 5a-d or 
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phenyl ring i.e., 6a to 6d has demonstrated variation in activity due to increase in the dimension of 
the group at this position of the molecule. Compounds with phenyl ring exhibited considerable 
anticonvulsant activity in comparison to methyl group. The amplified anticonvulsant activity of 
compounds 6a-d may be endorsed to the presence of phenyl substitution, which might be 
accountable for additional van der Waals bonding to the binding site. The designed and synthesized 
the compounds with keeping a fact in mind that a number of clinically active anticonvulsants 
possess a nitrogen hetero atomic system with one or two phenyl rings and at least one carbonyl 
group in their structure. The structure of the title compounds 4a-f 5a-d and 6a-d fulfilled all the 
pharmacophoric structural requirements i.e., presence of 5-{2-[(2,6-dichlorophenyl) amino] 
benzyl}-1,3,4-oxadiazol-2-yl moiety as hydrophobic portion, N as electron donor system and 
another hydrophobic distal aryl ring responsible for metabolism. Thus, the results confirmed the 
four binding site hypothesis for semicarbazones. In the present study, N1-(5-{2-[(2,6-dichloro- 
phenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-hydroxy phenyl) (phenyl) methanone]- 
semicarbazone emerged out as the most active compound, showing abroad spectrum of activity 
without any neurotoxicity (Rajak et al., 2009). 
NH
ClCl
O
N
N
NH2
   
NH
ClCl
O
N
N
HN
O
NH2
   
NH
ClCl
O
N
N
HN
O
NH NH2
 
       1                      2                               3 
NH
O
NN
N
H
NH
O
N
ClCl
NH
O
NN
N
H
NH
O
N
ClCl
NO2  
                    4a                                  4b 
NH
O
NN
N
H
NH
O
N
ClCl
OH
NH
O
NN
N
H
NH
O
N
ClCl
CH3  
                4c                                         4d 
  
 
 
Ivy Union Publishing | http: //www.ivyunion.org April 8, 2015 | Volume 1 | Issue 1  
Asif M. American Journal of Current Organic Chemistry 2014, 1:37-59 Page 6 of 23 
NH
O
NN
N
H
NH
O
N
ClCl
OCH3
NH
O
NN
N
H
NH
O
N
ClCl
Cl  
                    4e                                 4f 
NH
O
NN
N
H
NH
O
N
CH3
ClCl
OH
NH
O
NN
N
H
NH
O
N
CH3
ClCl
OCH3  
                       5a                              5b 
NH
O
NN
N
H
NH
O
N
CH3
ClCl
NO2
NH
O
NN
N
H
NH
O
N
CH3
ClCl
Cl  
                      5c                                   5d 
NH
O
NN
N
H
NH
O
N
ClCl
NH
O
NN
N
H
NH
O
N
ClCl
OH  
                     6a                                  6b 
  
 
 
Ivy Union Publishing | http: //www.ivyunion.org April 8, 2015 | Volume 1 | Issue 1  
Asif M. American Journal of Current Organic Chemistry 2014, 1:37-59 Page 7 of 23 
NH
O
NN
N
H
NH
O
N
ClCl
NO2
NH
O
NN
N
H
NH
O
N
ClCl
OCH3  
                   6c                                  6d 
A series of novel N1-(5-{2-[(2,6-dichlorophenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)- 
N4-(4-substitutedbenzaldehyde)-semicarbazone 4a-f, N1-(5-{2-[(2,6-dichlorophenyl) amino] 
benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-substitutedphenyl)ethanone]-semicarbazone 5a-d and 
N1-(5-{2-[(2,6-dichlorophenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-substituted pshenyl) 
(phenyl)methanone]-semicarbazone 4a-f, 5a-d and 6a-d were synthesized to meet structural 
requirements necessary for anticonvulsant activity. Our results val idated that the pharmacophore 
model with four binding sites is vital for anticonvulsant activity. These new facts might be 
expedient in the future research and development of semicarbazones as novel anticonvulsants.  
The anticonvulsant activity evaluation of a series of 7-alkoxy-triazolo-[3,4-b]benzo[d]thiazoles 
(7a-u) viz 7-Ethoxyl-Triazolo-[3,4-b] Benzo[d]Thiazole (7a), 7-Propoxy-Triazolo-[3,4-b] Benzo 
[d]Thiazole (7b), 7-Butoxy-Triazolo-[3,4-b]Benzo[d]Thiazole (7c), 7-Pentyloxy-Triazolo-[3,4-b] 
Benzo[d]Thiazole (7d), 7-Hexyloxy-Triazolo-[3,4-b]Benzo[d] Thiazole (7e), 7-Heptyloxy- 
Triazolo-[3,4-b]Benzo[d]Thiazole (7f), 7-Octyloxy-Triazolo-[3,4-b] Benzo[d] Thiazole (7g), 
7-Decyloxy-Triazolo-[3,4-b]Benzo[d]Thiazole (7h), 7-Dodecyloxy-triazolo-[3,4-b]benzo [d] 
thiazole (7i), 7-Benzyloxy-triazolo-[3,4-b]benzo[d]thiazole (7j), 7-(2-Fluoro benzyloxy)-triazolo- 
[3,4-b]benzo[d]thiazole (7k), 7-(3-Fluorobenzyloxy)-triazolo-[3,4-b]benzo [d]thiazole (7l), 
7-(4-Fluorobenzyloxy)-triazolo-[3,4-b]benzo[d]thiazole (7m), 7-(2-Chloro-benzyloxy)-triazolo-[3, 
4-b]benzo[d]thiazole (7n), 7-(3-Chlorobenzyloxy)-Triazolo-[3, 4-b] Benzo[d]Thiazole (7o), 
7-(4-Chlorobenzyloxy)-Triazolo-[3,4-b]Benzo[d]Thiazole (7p), 7-(2-Bromobenzyloxy)-Triazolo- 
[3,4-b]Benzo[d]Thiazole (7q), 7-(3-Bromobenzyloxy)-Triazolo-[3, 4-b]Benzo[d]Thiazole (7r), 
7-(4-Bromobenzyloxy)-Triazolo-[3,4-b]Benzo[d]Thiazole (7s), 7-(4-Methylbenzyloxy) -Triazolo- 
[3,4-b]Benzo[d]Thiazole (5t) and 7-(4-Methoxybenzyloxy)-Triazolo-[3,4-b]Benzo[d]Thiazole (7u). 
Most compounds exhibited good anticonvulsant activity in the Maximal electroshock (MES) test. 
And the structure-activity relationships (SAR) were analyzed. Among the compounds studied, 
compound (7g) was found to be the most potent compound with a median effective dose (ED50) 
value of 8.0 mg/kg and a protective index (PI) value of 15.0, possessing better anticonvulsant 
activity and higher safety than marketed drugs carbamazepine and phenytoin. The mechanism study 
of compound 7g showed that it displayed broad spectrum activity in several models, and it is likely 
to have several mechanisms of action (including inhibiting voltage-gated ion channels and 
GABA-ergic activity). The anticonvulsant activity of 7-alkoxyl-4H-[1,2,4]triazolo [4,3-d]benzo 
[b][1,4]thiazines (Zhang et al., 2010), Among these compounds, 7-(2-fluorobenzyloxy)-4H- 
[1,2,4]triazolo[4,3-d]benzo[b][1,4]thiazine was the most active compound with an ED50 of 17.0 
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mg/kg and a protective index (PI; TD50/ED50) of 14.3 in the MES. With the intent to discover 
effective compounds with lower neurotoxicity, a series of 7-alkoxy-triazolo-[3,4-b] benzo[d] 
thiazoles, the ring contraction analogues of 7-alkoxyl-4H-[1,2,4]triazolo [4,3-d]benzo[b] 
[1,4]thiazines through removal of a CH2, were anticipated to possess a better anticonvulsant 
activity. Their anticonvulsant activity was evaluated using the MES test in mice and their 
neurotoxicity was evaluated with the rotarod test. For explaining the possible mechanism of action, 
the most active compound (7g) was tested in Pentylenetetrazole (PTZ), Isoniazid (ISO), and 
Bicuculline (BIC) induced seizure tests. 
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As with any other class of drugs, the preclinical discovery and development of a new chemical 
entity for the treatment of epilepsy rely heavily on the use of predictable animal models. At the 
present time, there are three in vivo models that are routinely used by most AED discovery 
programs. They include the maximal electroshock seizure (MES), the subcutaneous 
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pentylenetetrazol (scPTZ), and the kindling model. Of these, the MES and scPTZ seizure models 
represent the two animal seizure models, which are most widely used in the search for new AEDs 
(White. 2003; Levy et al., 1995). In this study, the MES seizure model was used for preliminary 
(phase I) screening of compounds 7a-7s. All of the compounds except were active in the MES test, 
indicative of their ability to prevent seizure spread. Among those compounds, four compounds 
7d-7g showed prominent anticonvulsant activity exhibiting protection against MES-induced seizure 
at the dose of 10 mg/kg. At the dose of 30 mg/kg, compounds 7b-7g, 7j, and 7k showed protection. 
At the dose of 100 mg/kg, most compounds showed protection except 7i, 7o-7p, and 7s. 
Compounds 7i, 7o-7p, and 7s exhibited comparatively lower anticonvulsant activity at the dose of 
300 mg/kg. None of the compounds showed protection in the 4 h period. As a result of preliminary 
screening, compounds 7a–g, 7j-7k, 7r, and 7t were subjected to the next phase of trials concerning 
quantification of their anticonvulsant activity (indicated by ED50) and neurotoxicity (indicated by 
TD50) in mice. Results of the quantitative test for the selected compounds, along with the data on 
the standard drug carbamazepine and phenytoin. Among the tested compounds, 
7-octyloxy-triazolo-[3, 4-b]benzo[d] thiazole (7g), which gave an ED50 value of 8.0 mg/kg and a 
TD50 value of 120.0 mg/kg resulting in a higher protective index (PI) value-that is TD50/ED50 = 
15.0, was the most active and promising compound in this study. With an ED50 value of 11.6 and 
PI value of 11.3, compound 7f was equipotent to carbamazepine in activity and safer than 
carbamazepine. Though Compounds 7j and 7k showed the lower activity compared to 
carbamazepine or phenytoin, they exhibited higher PI value than carbamazepine and phenytoin. 
Analyzing the activity of the synthesized compounds, the following structure–activity relationships 
(SAR) were obtained.  
Compounds 7a-7i were triazolo-[3, 4-b]benzo[d]thiazole molecules substituted by alkoxyl chains. 
The length of the alkyl chain appeared to have a direct impact on anticonvulsant activity of these 
derivatives. From compounds 7a-g, as the alkyl chain length increased, ED50 gradually increased, 
with the compound 7g (with the noctyloxy substituted group) being the most active. The trend 
reversed, however, when the alkyl chain had more than eight carbon atoms. Obviously, in this study 
the activity curve of the alkyl chain substituted derivatives is bell -shaped with a maximum activity 
peak. Compound 7g, with the maximum activity peak, probably reflected the optimal partition 
coefficient associated with the easiest crossing of the biological membranes. Compounds 7j-u were 
triazolo-[3, 4-b]benzo[d]thiazole molecules substituted by benzyloxy groups. The activity of them 
was comparatively weaker than that of the compounds mentioned above. With the exception of 
compounds 7j, 7k, 7r, and 7t, which exhibited the anticonvulsant activity with ED50<100mg/kg, 
the rest showed weak activity at the dose of 100 or 300mg/kg. Among 7j-u, compound 7g was the 
most promising compound with an ED50 of 21.9 mg/kg, TD50 of 262.9 mg/kg and PI of 12.0. 
Comparing the derivatives with different F-substitution positions on the benzyl ring, their activity 
order was o-F > p -F > m -F. Activity order of the Cl and Br substituted derivatives were o-Cl > m 
-Cl > p-Cl and m-Br > o-Br > p-Br, respectively. Two electron-donor containing derivatives 7t and 
7u were also designed and prepared, containing p-CH3 and p-OCH3. The ED50 value of 7t was 
65.5mg/kg. And 7u showed weak activity at the dose of 100mg/kg. They both decreased the activity 
compared to 7j, having non-substituted in the ring of benzyl group (Deng et al., 2010). 
Most compounds are highly potent in the MES test, and the MES test is known to be sensitive to 
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sodium channel inhibitors (e.g. phenytoin, carbamazepine), which suggested that they may inhibit 
voltage-gated ion channels (particularly sodium channels). To further investigate the effects of the 
anticonvulsant activity in several different models and speculate about the possible else mechanism 
of anticonvulsant action, compound 7g was tested against convulsions induced by chemical 
substances, including PTZ, ISO, and BIC. Compound 7g was administered into mice i.p. at the dose 
of 30 mg/kg, which was higher than its ED50 value and far below its TD50 value. The reference 
drug carbamazepine was also administered i.p. at the dose of 30 mg/kg. In the sc -PTZ model, 
compound 7g thoroughly inhibited the clonic seizures, tonic seizures and lethality induced by 
sc-PTZ, while the reference drug carbamazepine did not inhibit the clonic seizures induced by 
sc-PTZ. Compound 7g, exhibiting high anticonvulsant activity in the MES and sc-PTZ model 
which are most widely used in the search for new AEDs, suggested that it real ly possessed a good 
anticonvulsant profile. In the isoniazid model, carbamazepine inhibited the clonic seizures, tonic 
seizures and death induced by isoniazid at the rates of 40%, 100% and 100%, respectively; and 
compound 7g showed inhibition of the clonic seizures, tonic seizures and death induced by 
isoniazid at the rates of 40%, 80% and 100%, respectively. Carbamazepine and 7g both exhibited 
protection activity in the isoniazid model. PTZ and ISO have been reported to produce seizures by 
inhibiting γ-aminobutyric acid (GABA) neurotransmission. GABA is the main inhibitory 
neurotransmitter in the brain, and is widely implicated in epilepsy. Inhibition of GABAergic 
neurotransmission or activity has been shown to promote and facilitate seizures (Gale. 1992), while 
enhancement of GABAergic neurotransmission is known to inhibit or attenuate seizures. The 
findings of the present study suggest that the newly synthesized compound 7g might inhibite or 
attenuate PTZ-induced seizures and isoniazid-induced seizures in mice by enhancing GABAergic 
neurotransmission. Bicuculline (BIC) induced seizure model was also used to evaluate the 
anticonvulsant profile of compound 7g. In the BIC induced seizure model, both carbamazepine and 
7g inhibited the tonic seizures and death, but did not inhibit clonic seizures. Carbamazepine showed 
inhibition at the rate of 0%, 100% and 80% of the clonic seizures, tonic seizures and death, 
respectively. And 7g showed inhibition at the rates of 0%, 80% and 50%, respectively. In this test, 
compound 7g showed a positive inhibition to the tonic seizures induced by BIC, and half protection 
against animal death induced by BIC. BIC is a competitive antagonist of GABAA receptor. BIC 
produces convulsions through its antagonism of GABAA receptor. Compound 7g can inhibit the 
seizures induced by BIC, which suggested that it exerts anticonvulsant activity partially through 
GABAA-mediated mechanisms. The 7-alkoxy-triazolo-[3,4-b]benzo[d]thiazoles have potent 
anticonvulsant activity in the MES test. Especially, compound 7g showed better anticonvulsant 
activity and higher safety than marketed drugs carbamazepine and phenytoin. In addition, 
compound 7g demonstrated antagonistic activity against seizures induced by PTZ, Isoniazid, and 
Bicuculline. Compound 7g are likely to have several mechanisms of action (including inhibit 
voltage-gated ion channels and GABA-ergic activity). 
A series of 2-(1H-Benzotriazol-1-yl)-N'-[substituted]acetohydrazides (8a-j) viz 2-(1H-Benzo- 
triazol-1-yl)-N'-(4-phenoxybenzylidene)acetohydrazide (8a), 2-(1H-Benzo-triazol-1-yl)- 
N'-[4-(4-nitrophenoxy)benzylidene]acetohydrazide (8b), 2-(1H-Benzotriazol-1-yl)-N'-[4-(4 methyl- 
phenoxy)benzylidene]acetohydrazide (8c), 2-(1H-Benzotriazol-1-yl)-N'-[4-(4-chloro 
phenoxy) benzylidene]acetohydrazide (8d), 2-(1H-Benzotriazol-1-yl)-N'-[4-(4-bromo-phenoxy) 
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benzylidene]acetohydrazide (8e), 2-(1H-Benzotriazol-1-yl)-N'-[4-(4-fluoro-phenoxy) benzylidene] 
acetohydrazide (8f), 2-(1H-Benzotriazol-1-yl)-N'-[4-(4-chloro-3-methyl-phenoxy) benzylidene] 
aceto- hydrazide (8g), 2-(1H-Benzotriazol-1-yl)-N'-[4-(naphthalen-2-yloxy) benzylidene] 
acetohydrazide (8h), N'-[4-(1,3-Benzodioxol-5-yloxy) benzylidene]-2-(1Hbenzotriazol-1-yl) 
acetohydrazide (8i) and 2-(1H-Benzotriazol-1-yl)-N'-[(3Z)-2-oxo-1,2-dihydro-3H-indol 
-3-ylidene]acetohydrazide (8j), were  synthesized keeping in view the structural requirement of 
pharmacophore and evaluated for anticonvulsant activity and neurotoxicity. The anticonvulsant 
activity of the compounds was assessed using the 6 Hz psychomotor seizure test. The neurotoxicity 
was assessed using the rotarod method. The most active compound of the series was (8i), which 
showed good activity with 75 % protection (3/4, 0.5 h) at a dose of 100 mg/kg in mice. None of the 
compounds exhibited neurotoxicity. Synthesis and biological activity of 1H-benzotriazole analogs 
as inhibitors of the NTpase/helicase and some related Flavivirade have been extensively 
investigated (Bretner et al., 2005). In the twenties, 1H-benzotriazole moiety containing compounds 
such as benzotriazole and benzofuran-based heterocycles (Dawood et al., 2006), 1-(2-Amino 
phenyl)-2-[5-(2-benzotriazol-2-yl-ethyl)-tetrazol-2-yl]-ethanone and 1-(4-Amino phenyl)-2- 
[5-(2-benzotriazol-2-yl-ethyl)-tetrazol-2-yl]-ethanone (Rajasekaran et al., 2006) were reported as 
potential anticonvulsants. In fact, these evidences suggest that the 1H-benzotriazole moiety, 
possesses a pharmacophoric character for anticonvulsant activity. In addition, the 
4-(2-phenoxyphenyl)semicarbazones were reported as potential anticonvulsants (Shafiee et al., 
2009). Continuing our studies on benzfused derivatives that are attractive candidates as 
anticonvulsant agents (Kumar et al., 2011), we designed a series of functionalized 
2-(1H-Benzotriazol-1-yl)-N'-[substituted] acetohydrazides compounds 8a-j, exploring 
1H-benzotriazole, as starting material. The rational design of these new derivatives 8a-j, was 
planned by molecular hybridization of substituted 1H-benzotriazole 8g, and 4-(aryloxy) phenyl 
semicarbazones 8f. Based on the literature review, we are the first to report the synthesis and 
anticonvulsant activities of 2-(1H-Benzotriazol-1-yl)-N'-[substituted] acetohydrazides. All the 
synthesized compounds comprised of the essential pharmacophoric elements that are necessary for 
good anticonvulsant activity (Unverferth et al., 1998). In addition, their anticonvulsant activity was 
evaluated by using 6 Hz psychomotor seizure test in mice. The rotorod assay was performed in 
mice to evaluate the neurotoxicity of the compounds.  
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The synthesized 2-(1H-Benzotriazol-1-yl)-N'-[substituted] acetohydrazides 8a-j were subjected to 
anticonvulsant screening by 6 Hz psychomotor seizure or minimal clonic seizure test to identify their 
anticonvulsant activity at five different time points, i.e., 0.25 h, 0.5 h, 1.0 h, 2.0 h and 4.0 h after i.p. 
administration in mice at a dose of 100 mg/kg. As observed from the results of various tested 
2-(1H-Benzotriazol-1-yl)-N'-[substituted] acetohydrazides, compound 8i was the most active one in this 
series with 75 % protection (3/4, 0.5 h) at a dose of 100 mg/kg. At a dose of 100 mg/kg, compounds 8d, 
8e and 8h showed 50% protection (2/4) at a time point of 1.0 h, 0.5 h and 0.5 h respectively. Other 
compounds showed mild to moderate activity. These active compounds contain 
1,3-benzodioxol-5-yl,4-chlorophenyl,4-bromophenyl and naphthalen-2-yl substitution attached to basic 
molecular structure. None of the compounds showed neurotoxicity in the highest administered dose 
(Kumar and Tripathi. 2012). A series of 2-(1H-Benzotriazol-1-yl)-N'-[substituted] acetohydrazide was 
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designed, synthesized, and their anticonvulsant activity was evaluated after intraperitoneal administration 
in 6 Hz psychomotor seizure test. The compound 8i displayed significant protection and emerged as a 
lead in this series. Further, compounds 8d, 8e and 8h came out as a potential candidate for further 
investigation. However, further studies need to be carried out to ascertain the precise mechanism of action 
of anticonvulsant activity of these molecules (Kumar and Tripathi. 2012). 
Various 6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine derivatives (9a-n) were designed keeping in 
view the wide bioactivities of 1,2,4-triazoles and their fused heterocyclic derivatives. All 
6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines (9a-n)namely 3-ethyl-6-phenyl-7H-[1,2,4]triazolo 
[3,4-b][1,3,4]thiadiazine (9a), 3-methyl-6-phenyl-7H-[1,2,4]triazolo [3,4-b][1,3,4]thiadiazine (9b), 
6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (9c), 6-(2-fluorophenyl)-7H-[1,2,4]triazolo[3,4-b] 
[1,3,4]thiadiazine (9d), 6-(4-fluorophenyl)-7H-[1,2,4] triazolo[3,4-b][1,3,4]thiadiazine (9e), 
6-(2-chlorophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazine (9f), 6-(3-chlorophenyl)-7H-[1,2,4] 
triazolo [3,4-b][1,3,4]thiadiazine (9g), 6-(4-chloro-phenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
(9h), 6-(2,4-dichlorophenyl)-7H-[1,2,4] triazolo[3,4-b][1,3,4]thiadiazine (9i), 6-(2-bromophenyl)-7H- 
[1,2,4]triazolo[3,4-b] [1,3,4] thiadiazine (9j), 6-(3-bromophenyl)-7H-[1,2,4] triazolo [3,4-b] [1,3,4] 
thiadiazine (9k), 6-(4-bromo-phenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (9l), 6-(4-methyl- 
phenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (9m) and 6-(4-methoxyphenyl)-7H-[1,2,4] triazolo 
[3,4-b][1,3,4]thiadiazine(9n)have been evaluated for their anticonvulsant activity against MES-induced 
seizures. The results showed that most of the compounds displayed some degree of anticonvulsant activity. 
Among them, compound (9h) was the most promising compound with an ED50 value of 40.9 mg/kg and 
a PI value of 6.5. The ambient nucleophilic centers presented in 3-substituted-4-amino-5 
-mercapto-1,2,4-triazoles render them as useful synthons for the synthesis of various N-bridged 
heterocycles (Smicius et al., 2007). The 6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine derivatives 
(9a-9n) were evaluated for their anticonvulsant activities. In the phase I preliminary anticonvulsant 
screening, Al most all the compounds (except 9a) showed some degree of protection in MES screen 
which was the indicative of the good ability of these compounds to prevent the seizure spread. Majority of 
the compounds were active at a dose of 100 mg/kg after 0.5 h. These include compounds 9c-h, 9j and 9k. 
Compounds 9b, 9i, 9m-n were showed protection from seizure at the dose 300 mg/kg after 0.5 h. None of 
the compounds showed protection at 4 h which indicated the nature of these compounds having quick 
onset and short duration of action. In the neurotoxicity screening, compounds that were devoid of 
minimal motor impairment at any dose were 9a, 9b, 9j, and 9l. Rest of the compounds showed some 
degree of neurotoxicity. On the basis of the considerable anticonvulsant promise suggested in phase I 
testing, compounds 9c-h, 9j and 9k were subjected to phase II trials for quantification of their 
anticonvulsant activity (indicated by ED50) and neurotoxicity (indicated by TD50) in mice. Results of the 
quantitative test for selected compounds, along with the data on the standard drug carbamazepine and 
valproate, are reported. All the compounds showed weaker anticonvulsant activity compared to currently 
used antiepileptic drugs carbamazepine but better than valproate. 6-(4-Chlorophenyl) 
-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (9h) possessed nice anti-MES activity with ED50 of 40.9 
mg/kg, and a protective index of 6.5, which was equal to carbamazepine and better than that of valproate. 
The design of compounds was in following way. Compounds 9a-9c were first prepared to confirm our 
presumption that the exposure of triazole is very important for the anticonvulsant activity. The triazole 
exposed (no substitute in 5th position), and the phenyl ring attached to the thiadiazine moiety was 
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substituted with different electron withdrawing groups and electron releasing groups at different positions 
expecting to find some compounds with better anticonvulsant activity. The derivatives with chloro group 
attached to the phenyl ring were the most active of the series. The effect of electron withdrawing groups 
was found to be uncertain on the anticonvulsant activity. Compounds with electron releasing groups in 
phenyl ring decreased anticonvulsant activity (Song et al., 2011). 
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A series of benzothiazole sulfonamides, thiosemicarbazones and guanidine derivatives were 
synthesized 2-Amino-1, 3-benzothiazole derivatives (10a-c, 6-Sulfamido 1,3 benzothiazo 2-yl 
thiosemicarbazide derivatives 11a-c and N-[(1, 3-benzothiazole-2-ylamino)(imino) methyl] -nitro 
benzene sulfonamide 12a-b by different pathways and tested for the neurotoxicity studies by the 
Rotarod method. The minimal motor impairment, the significant results were found with 
compounds (11c) and (10c). Some of these compounds also showed anticonvulsant  activity by 
decreasing the duration of convulsions in albino mice. Compound (10c), (11c) and also compound 
(10b) were found to be increased in the onset of convulsion and other test drugs showed moderate 
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protection and animals were recovered in these groups. Various 2-Amino-1, 3-benzothiazole 
derivatives (Gunakkunru and Verma. 2007; Jiminet et al., 1994; Maleki and Salehabadi. 2010; 
Fukuyama et al., 1997). Some compounds were showing positive results in this test. In the minimal 
motor impairment by rotarod, the significant results were found with (11c) and (10c). When these 
test drugs were compared to standard drug diazepam (80.15%), % decrease in fall off time was 
49.66%, and 24.96%. The compounds were further screened for anticonvulsant activity by PTZ 
evoked convulsion. Anticonvulsant studies on some of the compounds were carried out by PTZ 
animal model (Wagle et al., 2009; Stables and Kupferberg. 1995; Abraham. 2003). In the 
anticonvulsant screening of test drugs, onset of action and duration of convulsion were observed to 
show the protection by test drugs. Compound (10c) and compound (11c) were increasing the onset 
of convulsion and other test drugs were showing moderate protection, animals were recovered in 
these groups. Compound (10b) was also showing a decrease in duration of convulsion. These 
compounds are weak inhibitors; they may constitute leads for developing tighter binding 
compounds and may create a novel interest, in addition to the sulfonamide and sulfamate. The new 
applications of sulfonamides range from antiglaucoma agents with topical activity, to 
anticonvulsants, antipain, antiobesity, and antitumor agents/diagnostic tools for cancer. This idea is 
not widely accepted, there is potential to develop anti-infectives (antimalarials, antifungal, and 
antibacterial agents) belonging to the CAIs, targeting enzymes from various pathogens. It is thus, 
foreseeable that novel therapeutic applications will emerge in the near future (Sethi et al., 2011). 
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Discussion  
Epilepsy affects 1% of world’s population according to the epidemiological studies. Currently 
available AEDs produce satisfactory seizure control in 60–70% of patients (Perucen. 1996; Strine, 
et al., 2005). Several new AEDs like oxacarbazepine, vigabatrin, lamotrigine, gabapentin, 
topiramate, felbamate, rufinamide and levetiracetam have been put in clinical practice. Despite 
familiarity with established AEDs and the introduction of these new agents in the past decade, upto 
one third of epilepsy patients remain resistant to optimum drug treatment (Sabers and Gram. 2000). 
These facts triggered the search for newer more effective and less toxic AEDs. Only 75 -80% of 
epileptic patients may be provided with adequate seizure control with the help of the available 
AEDs. The therapeutic failure in 20-25% of patients and serious side effects in the available AEDs 
have stimulated intensive research on novel AEDs (Spear. 2001; Bootsma et al., 2009; Kennedy and 
Lhatoo. 2008). The 1,2,4-triazole nucleus is incorporated in wide variety of therapeutically agents, 
such as antimicrobial (Eswaran et al., 2009; Bayrak et al., 2009), anticonvulsant (Chen et al., 2007;  
Deng et al., 2010) and enzyme inhibition activities (Zhou et al., 2009; Owen et al., 2007). Although 
the current drugs provide adequate seizure control in many patients, it is roughly estimated that up 
to 28-30% of patients are poorly treated with the available AEDs (Kwan and Brodie. 2000; Spear. 
2001). Many AEDs have serious side effects (Rémi et al., 2010; Meador. 2003; Belcastro et al., 
2010; Bootsma et al., 2009; Kennedy and Lhatoo. 2008; Penovich and Willmore. 2009), and 
lifelong medication may be required. Toxicity, intolerance, and lack of efficacy are the limitations 
of the current AEDs. Therefore, the continued search for safer and more effective new AEDs is 
necessary (Loscher and Schmidt. 1994; Scheuer and Pedley. 1990).  
Conclusion  
In past years the discovery and development of antiepileptic drugs (AEDs) have been the noticeable 
research fields. The search for new compounds combining strong antiepileptic activity is in 
progress. Many derivatives have been discovered as potent AEDs and the structure activity 
relationship studies have been reported. The antiepileptic activity of ten newly synthesized in MES 
models of seizures in rats was investigated. For several decades, AEDs research has focused on 
identifying new potential AEDs based on their activity against single acute seizures induced by 
various stimulators, usually in mice and rats. All established have antiepileptic activity in at least 
MES model. Thus, this test may, in some way distinguish the potential utility of compounds against 
different seizure types. Antiepileptic drugs have greatly improved the lives of people with epile psy. 
Approximately 70% of the patients can achieve complete freedom from seizures with appropriate 
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treatment. The synthesized compounds confirmed the pharmacophore model requirements for the 
activity. 
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